Acute Ischemic Stroke Clinical Trial
Official title:
Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke
Verified date | July 2016 |
Source | University Hospital Inselspital, Berne |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Observational |
Stroke, a personal, familial, and social disaster, is the first cause of acquired
disability, the second cause of dementia, and the third cause of death worldwide. Its
associated socio-economic costs are astronomic. The burden of stroke is likely to increase,
given the aging of the population and the growing incidence of many vascular risk factors.
Therefore, apart from further development of stroke prevention and treatment strategies,
rational and effective tools for diagnosis, monitoring, and follow-up for stroke patients
have potential high long-term clinical and economic consequences.
For neuroradiological work-up, computed tomography (CT) or magnetic resonance imaging (MRI)
are used as gold standard techniques to detect presence or absence, effective state, and
extent of stroke. However, these techniques achieve simply a baseline study of ischemia
occurred and can deliver only a snapshot of brain parenchyma and vessels. Furthermore, their
rapid and actual availability, especially in primary hospitals, and their dynamic
capabilities and predictive values for further infarction are poor with critically ill
patients have to be repeatedly transferred to the scanning unit for each measurement.
Whereas CT examination is associated with x-ray radiation and may miss early detection of
stroke, MRI is associated with higher costs and not generally routinely and around-the clock
available in all the hospitals. Therefore, a simple, fast, repeatable, non-hazardous, and
non-invasive dynamic bedside tool for the detection of acute brain tissue hypoperfusion and
monitoring for potential further infarction or efficacy of thrombolysis either by systemic
intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) or by
selective intraarterial fibrinolysis and mechanical recanalization, both combined with or
without bridging after acute ischemic stroke, is strongly needed.
A promising alternative method of diagnosing stroke represents contrast-enhanced ultrasound
perfusion imaging (UPI). What makes UPI so valuable is the advantage of repeatedly and
non-invasively detecting brain tissue at risk for infarction by dynamic direct brain tissue
perfusion assessment and not by surrogate parameters, like blood flow velocity or vessel
diameter. Because of the possibility to screen and repeatedly measure the state of
perfusion, the chances increase to diagnose and monitor ischemic stroke and to define the
appropriate window for treatment. The perfusion analysis would also allow determination of
treatment results and guidance of rapid and adequate further therapy.
Therefore, the present pilot study in 40 patients is initiated. The objectives of this
observational diagnostic cohort trial are to evaluate feasibility and practicability of
repeated bedside assessments by contrast enhanced UPI in acute ischemic stroke patients and
to assess whether UPI can detect alterations in brain tissue perfusion before and after
recanalising therapy of strokes. Assessment of cerebral perfusion by CT or MRI serves as
reference and its results are compared to UPI data.
Status | Completed |
Enrollment | 33 |
Est. completion date | April 2016 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients with an indication for iv thrombolysis or endovascular treatment according to the current stroke guidelines of the University Hospital Bern - Age =18 - Written informed consent by patient or next of kin - Signed consent of independent physician Exclusion Criteria - Positive pregnancy test and breast feeding - Acute coronary syndromes, severe ischemic heart disease (requiring revascularization), severe aortic and mitral valve disease, severe congestive heart failure (NYHA >III/IV) - Severe pulmonary or renal dysfunction - Known allergy or adverse reaction to contrast material |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Neurosurgery, Bern University Hospital Bern | Bern |
Lead Sponsor | Collaborator |
---|---|
University Hospital Inselspital, Berne |
Switzerland,
Beck J, Raabe A, Lanfermann H, Berkefeld J, De Rochemont Rdu M, Zanella F, Seifert V, Weidauer S. Effects of balloon angioplasty on perfusion- and diffusion-weighted magnetic resonance imaging results and outcome in patients with cerebral vasospasm. J Neurosurg. 2006 Aug;105(2):220-7. — View Citation
Beck J, Raabe A, Lanfermann H, Seifert V, Weidauer S. Perfusion-weighted magnetic resonance imaging in patients with vasospasm: a useful new tool in the management of patients with subarachnoid hemorrhage. Neurosurgery. 2006 Mar;58(3):E590; author reply E590. — View Citation
Beck J, Raabe A, Lanfermann H, Seifert V, Weidauer S. Tissue at risk concept for endovascular treatment of severe vasospasm after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1779-81. — View Citation
Engelhardt M, Hansen C, Eyding J, Wilkening W, Brenke C, Krogias C, Scholz M, Harders A, Ermert H, Schmieder K. Feasibility of contrast-enhanced sonography during resection of cerebral tumours: initial results of a prospective study. Ultrasound Med Biol. 2007 Apr;33(4):571-5. — View Citation
Eyding J, Krogias C, Meves S, Przuntek H, Postert T. Quantitative ultrasonographic evaluation of cerebral perfusion in acute stroke is possible. Stroke. 2004 Nov;35(11):2432-3; author reply 2433. Epub 2004 Sep 16. — View Citation
Eyding J, Krogias C, Schöllhammer M, Eyding D, Wilkening W, Meves S, Schröder A, Przuntek H, Postert T. Contrast-enhanced ultrasonic parametric perfusion imaging detects dysfunctional tissue at risk in acute MCA stroke. J Cereb Blood Flow Metab. 2006 Apr;26(4):576-82. — View Citation
Kern R, Diels A, Pettenpohl J, Kablau M, Brade J, Hennerici MG, Meairs S. Real-time ultrasound brain perfusion imaging with analysis of microbubble replenishment in acute MCA stroke. J Cereb Blood Flow Metab. 2011 Aug;31(8):1716-24. doi: 10.1038/jcbfm.2011.14. Epub 2011 Mar 2. — View Citation
Kopp R, Zürn W, Weidenhagen R, Meimarakis G, Clevert DA. First experience using intraoperative contrast-enhanced ultrasound during endovascular aneurysm repair for infrarenal aortic aneurysms. J Vasc Surg. 2010 May;51(5):1103-10. doi: 10.1016/j.jvs.2009.12.050. — View Citation
Seidel G, Meyer-Wiethe K, Berdien G, Hollstein D, Toth D, Aach T. Ultrasound perfusion imaging in acute middle cerebral artery infarction predicts outcome. Stroke. 2004 May;35(5):1107-11. Epub 2004 Mar 18. — View Citation
Wiesmann M, Meyer K, Albers T, Seidel G. Parametric perfusion imaging with contrast-enhanced ultrasound in acute ischemic stroke. Stroke. 2004 Feb;35(2):508-13. Epub 2004 Jan 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with detection of cerebral hypoperfusion before and after thrombolytic treatment and correlation to established diagnostic gold standard CT- or MRI-perfusion studies by measurement of time to peak values | 1 day after intervention | No | |
Secondary | Number of Patients with Adverse Events as a Measure of Safety and Tolerability and detection of early clinical outcome by NIHSS | 1 day after intervention | No | |
Secondary | Quantitative analysis of metric parameters of UPI | 1 day after intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |